The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.

CEO Vas Narasimhan argued that the healthcare debate in the U.S. needs to shift away from list prices and net prices toward a ...

At Davos 2026, Novartis CEO Vas Narasimhan said regulatory clarity in the US and a rapid reshaping of the company’s supply ...

Jan 20 (Reuters) - Novartis CEO Vas Narasimhan told CNBC on Tuesday he expects the drugmaker's agreement with the U.S.

Novartis CEO says US manufacturing investments and a federal agreement could limit tariff exposure as proposed Trump levies target Europe.

Novartis CEO Vas Narasimhan discusses AI-driven innovation, Hyderabad's key role, and future breakthroughs in neuroscience at ...

Monday - Friday, 08:00 - 11:00 CET | 14:00 - 17:00 HK/SG Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity Biosciences, and ...

LONDON (Reuters) -Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm getting late-stage data for its muscle disorder treatment next ...

Bridgewater Associates founder Ray Dalio said President Trump's aggressive foreign policy tactics could end up scaring off ...

Jan 13 (Reuters) - Novartis (NOVN.S), opens new tab will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said at a major industry conference ...

Novartis’ continuing search for new ways to take drugs into the brain has resulted in a $1.7 billion deal with SciNeuro Pharmaceuticals.